CONTEXT: Cyanide is a component of smoke in residential and industrial fires, and accidental exposure to cyanide occurs in a variety of industries. Moreover, cyanide has the potential to be used by terrorists, particularly in a closed space such as an airport or train station. Current therapies for cyanide poisoning must be given by intravenous administration, limiting their use in treating mass casualties. OBJECTIVE: We are developing two new cyanide antidotes--cobinamide, a vitamin B(12) analog, and sulfanegen, a 3-mercaptopyruvate prodrug. Both drugs can be given by intramuscular administration, and therefore could be used to treat a large number of people quickly. We now asked if the two drugs would have an augmented effect when combined. MATERIALS AND METHODS: We used a non-lethal and two different lethal models of cyanide poisoning in mice. The non-lethal model assesses neurologic recovery by quantitatively evaluating the innate righting reflex time of a mouse. The two lethal models are a cyanide injection and a cyanide inhalation model. RESULTS: We found that the two drugs are at least additive when used together in both the non-lethal and lethal models: at doses where all animals died with either drug alone, the combination yielded 80 and 40% survival in the injection and inhalation models, respectively. Similarly, drug doses that yielded 40% survival with either drug alone, yielded 80 and 100% survival in the injection and inhalation models, respectively. As part of the inhalation model, we developed a new paradigm in which animals are exposed to cyanide gas, injected intramuscularly with an antidote, and then re-exposed to cyanide gas. This simulates cyanide exposure of a large number of people in a closed space, because people would remain exposed to cyanide, even after receiving an antidote. CONCLUSION: The combination of cobinamide and sulfanegen shows great promise as a new approach to treating cyanide poisoning.
CONTEXT: Cyanide is a component of smoke in residential and industrial fires, and accidental exposure to cyanide occurs in a variety of industries. Moreover, cyanide has the potential to be used by terrorists, particularly in a closed space such as an airport or train station. Current therapies for cyanidepoisoning must be given by intravenous administration, limiting their use in treating mass casualties. OBJECTIVE: We are developing two new cyanide antidotes--cobinamide, a vitamin B(12) analog, and sulfanegen, a 3-mercaptopyruvate prodrug. Both drugs can be given by intramuscular administration, and therefore could be used to treat a large number of people quickly. We now asked if the two drugs would have an augmented effect when combined. MATERIALS AND METHODS: We used a non-lethal and two different lethal models of cyanidepoisoning in mice. The non-lethal model assesses neurologic recovery by quantitatively evaluating the innate righting reflex time of a mouse. The two lethal models are a cyanide injection and a cyanide inhalation model. RESULTS: We found that the two drugs are at least additive when used together in both the non-lethal and lethal models: at doses where all animals died with either drug alone, the combination yielded 80 and 40% survival in the injection and inhalation models, respectively. Similarly, drug doses that yielded 40% survival with either drug alone, yielded 80 and 100% survival in the injection and inhalation models, respectively. As part of the inhalation model, we developed a new paradigm in which animals are exposed to cyanide gas, injected intramuscularly with an antidote, and then re-exposed to cyanide gas. This simulates cyanide exposure of a large number of people in a closed space, because people would remain exposed to cyanide, even after receiving an antidote. CONCLUSION: The combination of cobinamide and sulfanegen shows great promise as a new approach to treating cyanidepoisoning.
Authors: Mario Ernesto; A Paula Cardoso; Domingos Nicala; Estevão Mirione; Fernando Massaza; Julie Cliff; M Rezaul Haque; J Howard Bradbury Journal: Acta Trop Date: 2002-06 Impact factor: 3.112
Authors: Matthew Brenner; Jae G Kim; Jangwoen Lee; Sari B Mahon; Daniel Lemor; Rebecca Ahdout; Gerry R Boss; William Blackledge; Lauren Jann; Herbert T Nagasawa; Steven E Patterson Journal: Toxicol Appl Pharmacol Date: 2010-08-10 Impact factor: 4.219
Authors: Jangwoen Lee; Sari B Mahon; David Mukai; Tanya Burney; Behdod S Katebian; Adriano Chan; Vikhyat S Bebarta; David Yoon; Gerry R Boss; Matthew Brenner Journal: J Med Toxicol Date: 2016-09-15
Authors: Vikhyat S Bebarta; Matthew Brittain; Adriano Chan; Norma Garrett; David Yoon; Tanya Burney; David Mukai; Michael Babin; Renate B Pilz; Sari B Mahon; Matthew Brenner; Gerry R Boss Journal: Ann Emerg Med Date: 2016-12-29 Impact factor: 5.721
Authors: Susan M DeLeon; Jason D Downey; Diane M Hildenberger; Melissa O Rhoomes; Lamont Booker; Gary A Rockwood; Kelly A Basi Journal: Clin Toxicol (Phila) Date: 2017-09-19 Impact factor: 4.467
Authors: Bryant M Moeller; Daune L Crankshaw; Jacquie Briggs; Herbert T Nagasawa; Steven E Patterson Journal: Toxicol Lett Date: 2017-04-12 Impact factor: 4.372
Authors: Adriano Chan; Jingjing Jiang; Alla Fridman; Ling T Guo; G Diane Shelton; Ming-Tao Liu; Carol Green; Kristofer J Haushalter; Hemal H Patel; Jangwoen Lee; David Yoon; Tanya Burney; David Mukai; Sari B Mahon; Matthew Brenner; Renate B Pilz; Gerry R Boss Journal: J Med Chem Date: 2015-02-16 Impact factor: 7.446
Authors: Jingjing Jiang; Adriano Chan; Sameh Ali; Arindam Saha; Kristofer J Haushalter; Wai-Ling Macrina Lam; Megan Glasheen; James Parker; Matthew Brenner; Sari B Mahon; Hemal H Patel; Rajesh Ambasudhan; Stuart A Lipton; Renate B Pilz; Gerry R Boss Journal: Sci Rep Date: 2016-02-15 Impact factor: 4.379
Authors: Adrian Thompson; Michael Dunn; Robert D Jefferson; Kosala Dissanayake; Frances Reed; Rachael Gregson; Stephen Greenhalgh; R Eddie Clutton; Peter G Blain; Simon Hl Thomas; Michael Eddleston Journal: Clin Toxicol (Phila) Date: 2019-08-07 Impact factor: 4.467